Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
Portfolio Pulse from Vandana Singh
Sesame has launched a $249 monthly program offering compounded versions of Novo Nordisk's Wegovy, addressing supply shortages and high costs. This move provides a more affordable alternative to brand-name drugs, which can cost around $1,000 per month.
August 21, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly faces similar supply challenges as Novo Nordisk, which could lead to increased competition from compounded versions of its drugs, potentially affecting its market share.
Supply shortages for Eli Lilly's drugs could lead to increased competition from compounded versions, potentially affecting its market share and stock price negatively.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 60
NEGATIVE IMPACT
Novo Nordisk faces supply shortages for Wegovy, leading to Sesame's introduction of a more affordable compounded version. This could impact Novo Nordisk's sales and stock price negatively.
The introduction of a cheaper compounded version of Wegovy by Sesame could reduce demand for Novo Nordisk's brand-name drug, potentially impacting its sales and stock price negatively.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sesame's partnership with Costco for branded weight loss treatments is complemented by the new compounded medication program, potentially increasing customer traffic and sales for Costco.
The new program could drive more customers to Costco for weight loss treatments, potentially increasing sales and benefiting Costco's business.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50